Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4955877 | 0.90 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1LMNAKMT2A | |
| SCHEMBL28377873 | 0.89 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1LMNAKMT2A | |
| SCHEMBL16344760 | 0.89 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1LMNAKMT2A | |
| SCHEMBL8989009 | 0.88 | ALDH1A1 (0.61) | ALDH1A1MAPK1L3MBTL1LMNAKMT2A | |
| SCHEMBL24235719 | 0.87 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1LMNAKMT2A | |
| SCHEMBL22607077 | 0.87 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1LMNAKMT2A | |
| SCHEMBL18709165 | 0.87 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1LMNAKMT2A | |
| SCHEMBL17949819 | 0.87 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1LMNAKMT2A | |
| SCHEMBL8224834 | 0.87 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1LMNAKMT2A | |
| SCHEMBL12564571 | 0.87 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113874361-B | Compound with anticancer activity and preparation method thereof | 医药生命融合研究团 | 2024-07-12 | — | — | CN | claimed |
| CN-109553704-B | Catalyst component for olefin polymerization, catalyst and application | 中国石油化工股份有限公司 | 2021-04-13 | — | — | CN | claimed |
| CN-112538400-A | Vehicle-mounted fragrance and preparation method thereof | 广州汽车集团股份有限公司 | 2021-03-23 | — | — | CN | claimed |
| US-20080064873-A1 | Oxidizing an amino alcohol (obtained by ring opening the epoxy, aziding, reducing and reacting it with a carboxylic acid); stereoselectivity; protease inhibitors: antiallergens; anticarcinogenic and hypotensive agents | SEIKAGAKU KOGYO KABUSHIKI KAISHA D/B/A SEIKAGAKU CORPORATION (JP) | 2008-03-13 | — | — | US | claimed |
| JP-2004531459-A | — | — | 2004-10-14 | — | — | JP | claimed |
| EP-1366024-A2 | SULFOXIDE AND BIS-SULFOXIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-12-03 | — | — | EP | claimed |
| WO-2002030882-A2 | SULFOXIDE AND BIS-SULFOXIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | claimed |
| CN-113874361-B | Compound with anticancer activity and preparation method thereof | 医药生命融合研究团 | 2024-07-12 | — | — | CN | disclosed |
| US-20230233526-A1 | GRANZYME B INHIBITOR COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF SKIN BLISTERING AND/OR PEELING | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-07-27 | — | — | US | disclosed |
| CN-115948815-A | Preparation method of PLA degradable short fibers | 湖北博韬合纤有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-109082910-B | Dyeing property improving agent and method for producing dyed fiber product | 日华化学（中国）有限公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-114195517-A | Preparation method of additive-free high-purity yttrium oxide spherical particles for thermal spraying | 常州市卓群纳米新材料有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-112538400-A | Vehicle-mounted fragrance and preparation method thereof | 广州汽车集团股份有限公司 | 2021-03-23 | — | — | CN | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-7189756-B2 | Pyrrolidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| US-20050192347-A1 | Urea and thiourea compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2005-09-01 | — | — | US | disclosed |
| WO-2004089925-A1 | PI-3 KINASE INHIBITOR PRODRUGS | SEMAFORE PHARMACEUTICALS, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | ALDH1A1 1305/4885MAPK1 1850/4885L3MBTL1 4525/4885 |
| US-20080064873-A1 | Oxidizing an amino alcohol (obtained by ring opening the epoxy, aziding, reducing and reacting it with a carboxylic acid); stereoselectivity; protease inhibitors: antiallergens; anticarcinogenic and hypotensive agents | REN, CMA1, AKR1A1 | ALDH1A1 160/4885MAPK1 820/4885L3MBTL1 3551/4885 |
| US-20050192347-A1 | Urea and thiourea compounds and compositions for cholesterol management and related uses | PNLIP, FABP2, GPR119 | ALDH1A1 3862/4885MAPK1 3658/4885L3MBTL1 2126/4885 |
| US-20230233526-A1 | GRANZYME B INHIBITOR COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF SKIN BLISTERING AND/OR PEELING | GZMB, SERPINB1, CTSB | ALDH1A1 4771/4885MAPK1 2977/4885L3MBTL1 2251/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | ALDH1A1 2369/4885MAPK1 3042/4885L3MBTL1 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.